SmartPeptide
Start Free
MuscleLimited human evidence

CJC-1295 / Ipamorelin

Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Both compounds have pharmacology data in healthy adults showing increased endogenous GH pulses without affecting prolactin or cortisol much. Some PK/PD trials are published.

What's still experimental

Outcome trials (body composition, recovery, longevity) are sparse and mostly small. Long-term safety of repeated GH stimulation is not well established.

Anecdotal / community reports

Body-composition and sleep-quality reports are common; many users overlook baseline lifestyle and training.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “CJC-1295 / Ipamorelin”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “CJC-1295 / Ipamorelin”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C18H12F5N3O

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
76
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
3 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "CJC-1295 OR ipamorelin"

Europe PMC — 178 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
724
all years
Last 5 years
371
recent activity
Open access
638
freely readable
OA share
88%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “CJC-1295 OR ipamorelin” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
47,221
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Institutes of Health572 works
  • National Natural Science Foundation of China523 works
  • Canadian Institutes of Health Research231 works
  • National Science Foundation169 works
  • Heart and Stroke Foundation of Canada82 works
  • American Heart Association75 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 4 of 4 preprints indexed by Europe PMC.

Known risks

Carries risks similar to elevated GH (insulin resistance, edema). Not approved for general use.

Reported side effects

Water retention, injection-site irritation, headaches.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
2
FAERS, all years
Serious reports
2
100% of reports

Most-reported reactions

  • Drug Hypersensitivity
    1
  • Injection Site Abscess
    1
  • Product Dispensing Error
    1
  • Product Preparation Error
    1
  • Recalled Product Administered
    1

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Carries risks consistent with elevated GH (insulin resistance, edema, joint discomfort). Should be supervised; baseline IGF-1 and glycemic monitoring are reasonable.

Questions for your clinician

  • Should we baseline IGF-1, fasting glucose, and HbA1c?
  • How long is one cycle and how do we de-escalate?
  • What signs of insulin resistance should I watch for?

Editorially curated references

Discussions about CJC-1295 / Ipamorelin

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all CJC-1295 / Ipamorelin discussions Native, moderated, no buying or selling